Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 3/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | F7 | P08709 | 2/20 | 0.39 |
| ▸ | F3 | P13726 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2175685 | 1.00 | CA2 (0.57) | CA2MAPK1GRIK1GRIK2FFAR1 | |
| SCHEMBL17714572 | 0.98 | CA2 (0.55) | CA2MAPK1GRIK1GRIK2FFAR1 | |
| Hydrochloric Acid SCHEMBL30192502 | 0.98 | CA2 (0.55) | CA2MAPK1GRIK1GRIK2FFAR1 | |
| SCHEMBL17714573 | 0.98 | CA2 (0.55) | CA2MAPK1GRIK1GRIK2FFAR1 | |
| SCHEMBL8332014 | 0.94 | CA2 (0.59) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL8332015 | 0.94 | CA2 (0.59) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL29197403 | 0.87 | CA2 (0.55) | CA2MAPK1GRIK1GRIK2FFAR1 | |
| SCHEMBL9042224 | 0.87 | CHRM1 (0.57) | CA2MAPK1GRIK1GRIK2FFAR1 | |
| SCHEMBL27485865 | 0.86 | CA2 (0.52) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL30176796 | 0.86 | CA2 (0.50) | CA2MAPK1PPARGMAPTFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124944-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2009-12-02 | — | — | EP | claimed |
| WO-2008111010-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-09-18 | — | — | WO | claimed |
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-07-31 | — | — | US | disclosed |
| CN-115052866-B | Crystal form of nitrogen-containing heteroaromatic derivative free alkali | 上海翰森生物医药科技有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-113396147-B | Aromatic heterocyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240182444-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-06 | — | — | US | disclosed |
| CN-117940133-A | Therapeutic agents for degradation of mutant BRAF | C4医药公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-115353509-B | Nitrogen-containing heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-04-04 | — | — | US | disclosed |
| CN-115448923-B | Pyrimidine-fused ring compound, preparation method and application thereof | 上海青煜医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-113072499-B | Preparation method of 4-oxo-8-azaspiro [4.5] dec-2-ene-8-carboxylic acid tert-butyl ester (benzyl ester) | 南京药石科技股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-110655520-A | Pyrimido-cyclic compounds, process for their preparation and their use | 上海青煜医药科技有限公司 | 2020-01-07 | — | — | CN | disclosed |
| EP-2346867-A1 | PHOSPHODIESTARASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010046791-A1 | PHOSPHODIESTARASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-04-29 | — | — | WO | disclosed |
| EP-2124944-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2009-12-02 | — | — | EP | disclosed |
| EP-2121669-A2 | FURANONE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008111010-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008094574-A2 | FURANONE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| EP-1441720-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HEPATITIS C VIRUS NS3-NS4A PROTEASE, INCORPORATING A FUSED RING SYSTEM | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003035060-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HEPATITIS C VIRUS NS3-NS4A PROTEASE, INCORPORATING A FUSED RING SYSTEM | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CA2 2999/4885MAPK1 1561/4885GRIK1 3958/4885 |
| US-20240182444-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CA2 2999/4885MAPK1 1561/4885GRIK1 3958/4885 |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CA2 2999/4885MAPK1 1561/4885GRIK1 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.